Drug metabolism disorders

Deletions, duplications and other gene variations in the CYP2D6 and CYP2C19 genes play a major role in the metabolism of a significant number of prescription drugs.

For therapeutics metabolized primarily by products of these two genes, the AmpliChip CYP450 Test, for use on Affymetrix Instrumentation, helps clinicians determine individual therapeutic strategies and treatment doses.

Roche is committed to the ongoing support of laboratories and healthcare professionals in identifying genetic variance that can lead to more effective treatment and improved care for patients with drug metabolism disorders.